Drugs / Xuebijing
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT03238742 | Oct 2017 → Jul 2019 | infectious disease with sepsis | Southeast University, China | Completed | Met primary |
| Phase 4 | NCT02937974 | Oct 2016 → Dec 2018 | chronic obstructive pulmonary disease | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07026227 | Feb → Aug 2023 | acute kidney injury | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04993794 Comparator | Jan 2021 → Dec 2022 | aortic disorder, congenital heart disease, coronary artery disorder, heart valve disorder | Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xuebijing | “XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group,...” NCT04993794 ↗ |
| Known as | XBJ | “XBJ (Composed of Carthamus tinctorius L., Paeonia Lactifora Pall, Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, etc. Tianjin Chase Sun Pharmaceutical Group,...” NCT04993794 ↗1“the Chinese herbal-derived therapeutic Xuebijing (XBJ) injection is beneficial for patients with sepsis.” PMID 31467049 ↗ Aug 2019 |
| Action | Inhibit | “by inhibiting neutrophils and inflammatory cells” PMID 40830157 ↗ Aug 2025 |
| Modality | Traditional medicine (herbal / TCM) | “a Chinese herbal derived therapeutic” NCT04993794 ↗ |
| Route | Intravenous | “Xuebijing injection 50ml in 100ml of Normal Saline IV” NCT02937974 ↗ |